2026-01-26 - Analysis Report
**Company Overview**
Abbott Laboratories is a multinational health care company that offers a diverse range of health care products.

**Return Rate Comparison**
The cumulative return of the review stock (ABBOT Labs) is 53.87%, while the cumulative return of the comparison stock (S&P 500, VOO) is 126.41%. The divergence between the two is -72.50.

**Analysis of Provided Content**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 54.0% | 11.7% | 42.0% | 1.1 | 125.9B |
| 2017-2019  | 64.0% | 11.7% | 39.0% | 1.0 | 151.2B |
| 2018-2020  | 51.0% | 29.7% | 26.0% | 0.9 | 190.6B |
| 2019-2021  | 76.0% | 29.7% | 11.0% | 0.8 | 244.9B |
| 2020-2022  | 0.0% | 28.9% | -7.0% | 0.8 | 191.1B |
| 2021-2023  | -56.0% | 26.1% | -77.0% | 0.7 | 191.6B |
| 2022-2024  | -43.0% | 21.3% | -73.0% | 0.7 | 196.9B |
| 2023-2025  | 7.0% | 19.0% | -69.0% | 0.3 | 218.1B |

**Recent Stock Price Fluctuations**
- 5-day SMA: $115.93
- 20-day SMA: $123.00
- 60-day SMA: $125.07
- Close: $107.42

**Recent Market Fluctuations**
- Price change in the last market session: -1.1%
- Recent market fluctuation issue: Sharp decline

**Analysis of Technical Indicators**
- **MRI (Market Risk Indicator)**: 0.70 (High Investment Recommended)
- **RSI**: 16.92
- **PPO**: -1.48
- **Hybrid Signal**: Buy
- **Risk Level**: Medium
- **Recent Relative Divergence Change**: 0.00 (flat)
- **7-day Rank Change**: 0 (flat)
- **7-day Dynamic Expected Return Change**: 0.00 (flat)

**Analyst Opinions**
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 136.47 / 169.00 / 115.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |

**Revenue and Profitability Analysis**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |

**Capital and Profitability Analysis**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |

**Comprehensive Analysis**
Based on the analysis of return rate comparison, analysis of provided content, recent stock price fluctuations, technical indicators, analyst opinions, recent earnings analysis, revenue and profitability analysis, and capital and profitability analysis, it can be observed that:

* The review stock (ABBOT Labs) has a lower cumulative return compared to the comparison stock (S&P 500, VOO).
* The review stock has experienced sharp declines in recent market sessions.
* The technical indicators suggest a buy signal, but the market is at high risk with a risk level of Medium.
* Analyst opinions are generally positive with a mean of 1.76 (~Buy) and a target price of 136.47 / 169.00 / 115.00.
* Recent earnings analysis shows fluctuations in EPS and revenue.
* Revenue and profitability analysis shows a high profit margin of 55.36% in the latest quarter.
* Capital and profitability analysis shows a high ROE of 19.36% in the latest quarter.

Overall, the review stock (ABBOT Labs) seems to be experiencing fluctuations in its performance. However, the technical indicators and analyst opinions suggest a buy signal. Further research is required to understand the underlying factors driving this performance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.